<DOC>
	<DOCNO>NCT00431041</DOCNO>
	<brief_summary>The purpose study compare safety efficacy solifenacin oxybutynin immediate-release ( IR ) treatment overactive bladder ( OAB ) .</brief_summary>
	<brief_title>Study Compare Safety Efficacy Solifenacin With Oxybutynin Treatment Overactive Bladder ( VECTOR )</brief_title>
	<detailed_description>This study prospective randomize , double-blind , double-dummy , multicentre , 2-arm ( 1 Active , Active Control ) comparative parallel group study compare safety efficacy solifenacin oxybutynin immediate-release ( IR ) treatment overactive bladder ( OAB ) .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Adults 18 year old . Overactive bladder symptom great equal 3 month document 3day patient diary follow screen precede baseline visit : &gt; 1 urge episodes/24 hour ( average ) ; great equal 8 micturitions/24 hour ( average ) Urinary tract infection , chronic inflammation interstitial cystitis bladder stone Clinically significant outflow obstruction Uncontrolled narrow angle glaucoma , urinary , gastric retention Severe renal hepatic impairment Chronic severe constipation history diagnose GI obstructive disease Significant stress incontinence mixed stress/urge incontinence stress predominant factor Diagnosis history neurogenic bladder History bladder pelvic cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Oxybutynin immediate release</keyword>
	<keyword>Xerostomia</keyword>
	<keyword>Overactive bladder</keyword>
</DOC>